Tavneos Serious Liver Injury and Death Lawsuit Lawyers

FDA Safety Alert Raises New Concerns About Tavneos After Reports of Fatal Liver Injuries

What Parker Waichman LLP Found

• The FDA identified 76 reported cases of drug-induced liver injury with a reasonable causal association to Tavneos.
• Eight deaths have been reported, including three involving biopsy-confirmed vanishing bile duct syndrome.
• The FDA previously asked Amgen to voluntarily withdraw Tavneos, citing liver toxicity concerns and questions about the drug’s benefit-risk profile.
• The manufacturer declined the FDA’s request, maintaining confidence in the medication’s safety and effectiveness.
• Patients who suffered severe liver injuries after taking Tavneos may have legal rights to pursue compensation through a product liability lawsuit.

The U.S. Food and Drug Administration (FDA) has issued an important drug safety communication involving Tavneos (avacopan), a prescription medication approved to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. According to the FDA, postmarketing safety reports have identified eight deaths and 76 cases of drug-induced liver injury (DILI) that appear to have a reasonable causal association with the medication.

The FDA’s announcement has generated significant concern because many of these reported injuries were severe enough to require hospitalization. Several patients developed vanishing bile duct syndrome, a rare but potentially devastating liver condition that can permanently damage the liver and, in some cases, become fatal.

These developments have renewed questions regarding whether patients and healthcare providers received adequate warning about the full extent of Tavneos’ liver-related risks. The FDA had already recognized hepatotoxicity as a known adverse reaction during clinical testing. However, the agency now states that the severity and nature of these recently identified liver injuries represent new safety concerns.

Patients prescribed medications for serious autoimmune diseases often face difficult decisions. They depend on accurate safety information so they can weigh the benefits of treatment against potentially life-threatening complications. When new evidence suggests a medication may present greater risks than originally understood, patients deserve prompt notification and complete transparency.

The FDA’s latest communication highlights the importance of continued safety monitoring even after a medication has entered the marketplace. Drug approval does not end a manufacturer’s responsibility to monitor adverse events or update physicians and patients when significant safety concerns emerge.

What Is Tavneos?

Tavneos, known by its generic name avacopan, received FDA approval in 2021 for the treatment of adults with severe active ANCA-associated vasculitis. The medication works by blocking the complement C5a receptor, which plays an important role in inflammatory immune responses.

ANCA-associated vasculitis is a rare autoimmune disease in which the body’s immune system mistakenly attacks small blood vessels. This inflammation can affect multiple organs throughout the body, including the kidneys, lungs, nerves, skin, sinuses, and brain.

Without appropriate treatment, the disease may lead to permanent organ damage, kidney failure, respiratory complications, neurological injury, or death. Because of the seriousness of the disease, patients often require aggressive immunosuppressive therapy.

Tavneos was developed as a treatment intended to reduce inflammation while potentially allowing patients to decrease their reliance on high-dose corticosteroids. The drug represented an important therapeutic option for many individuals living with this uncommon but potentially life-threatening condition.

In 2022, Amgen acquired Tavneos through its $3.7 billion purchase of ChemoCentryx. Since then, the medication has generated hundreds of millions of dollars in annual sales.

While many patients may have benefited from treatment, the FDA’s recent safety communication illustrates how serious adverse effects can emerge after larger numbers of patients begin using a medication in real-world settings.

FDA Reports Eight Deaths and Dozens of Serious Liver Injuries

The FDA’s safety communication describes a concerning pattern of serious liver injuries associated with Tavneos.

According to the agency, there were:

• Eight reported deaths associated with drug-induced liver injury.
• Seventy-six reported cases of drug-induced liver injury with reasonable evidence suggesting a causal association.
• Seventy-four patients requiring hospitalization or experiencing other serious medical outcomes.
• Seven biopsy-confirmed cases of vanishing bile duct syndrome.
• Three deaths among patients diagnosed with vanishing bile duct syndrome.

Drug-induced liver injury is one of the leading reasons medications receive new warnings, market restrictions, or withdrawal from the marketplace. The liver performs numerous critical functions, including filtering toxins, metabolizing medications, producing proteins, and regulating numerous metabolic processes.

When medications damage liver tissue, patients may initially experience subtle symptoms before developing severe complications.

Potential warning signs may include:

• Yellowing of the skin or eyes.
• Dark-colored urine.
• Pale stools.
• Persistent nausea.
• Severe fatigue.
• Loss of appetite.
• Abdominal pain, particularly in the upper right side.

Because liver injury can progress rapidly, early diagnosis is often critical.

Understanding Drug-Induced Liver Injury

Drug-induced liver injury, commonly referred to as DILI, occurs when medications damage liver cells or interfere with normal liver function.

Some cases involve temporary elevations in liver enzymes that resolve after discontinuing the medication. Other cases become much more serious, resulting in permanent liver damage, liver failure, the need for liver transplantation, or death.

DILI remains one of the most difficult medication-related complications to predict because reactions can vary widely among patients.

Factors influencing severity may include:

• Existing liver disease.
• Other prescription medications.
• Underlying autoimmune disorders.
• Genetic susceptibility.
• Overall health.

One reason DILI presents significant challenges is that symptoms frequently resemble common illnesses during the early stages. Patients may dismiss fatigue, nausea, or abdominal discomfort until significant liver damage has already occurred.

Healthcare providers often monitor liver function using blood tests measuring enzymes such as ALT, AST, alkaline phosphatase, and bilirubin.

The FDA now recommends significantly increased monitoring for patients taking Tavneos.

Vanishing Bile Duct Syndrome Is a Rare but Potentially Devastating Condition

Among the most concerning findings identified by the FDA involves vanishing bile duct syndrome.

This uncommon disorder occurs when bile ducts inside the liver become progressively destroyed. Because bile helps eliminate waste products and aids digestion, destruction of these ducts can cause serious liver dysfunction.

As bile flow becomes impaired, patients may experience worsening liver injury, jaundice, malnutrition, severe itching, chronic fatigue, and progressive liver failure.

Some individuals recover after stopping the offending medication. Others suffer irreversible damage requiring liver transplantation.

According to the FDA, all seven patients diagnosed with biopsy-confirmed vanishing bile duct syndrome required hospitalization.

Three of those patients died.

These reports raise significant questions regarding whether additional warnings, earlier monitoring, or different prescribing recommendations could potentially have reduced patient harm.

FDA Previously Asked Amgen to Withdraw Tavneos

The FDA’s latest safety alert follows an earlier disagreement between federal regulators and Amgen.

In January, the FDA reportedly requested that Amgen voluntarily remove Tavneos from the market.

The agency cited concerns involving both liver toxicity and questions surrounding data from the clinical trial supporting the drug’s approval. Specifically, the FDA questioned how primary outcome data had been re-adjudicated for several patients during the pivotal clinical trial.

The regulator concluded that these issues affected the medication’s overall benefit-risk profile.

Amgen declined the FDA’s request.

The company publicly stated that it remained confident in Tavneos’ effectiveness and maintained that available clinical evidence and years of real-world data continued to support a favorable benefit-risk balance.

As of the FDA’s most recent safety communication, the agency has not announced whether additional regulatory action will occur.

The Importance of Post-Marketing Drug Safety Surveillance

Clinical trials provide valuable information before a medication reaches consumers. However, no clinical trial can identify every possible adverse reaction.

Many serious drug complications emerge only after tens of thousands of patients begin using a medication.

Post-marketing surveillance allows regulators to collect reports from:

• Drug manufacturers
• Hospitals
• Drug manufacturers.
• Family members.

As additional reports accumulate, patterns may emerge that were impossible to detect during earlier studies.

These ongoing safety reviews help regulators determine whether updated warnings, dosage changes, enhanced monitoring, restricted use, recalls, or market withdrawal become necessary.

The Tavneos safety communication illustrates why continued monitoring remains essential throughout a drug’s commercial life.

Potential Legal Claims Involving Dangerous Prescription Drugs

Patients who suffer serious injuries after taking prescription medications may have legal rights under product liability laws.

Drug manufacturers generally have a responsibility to adequately research their products, disclose known safety risks, monitor adverse events, and update prescribing information when new hazards become apparent.

Depending upon the evidence developed during an investigation, prescription drug litigation may involve allegations such as:

• Failure to provide adequate warnings.
• Defective drug design.
• Negligent safety monitoring.
• Failure to timely update prescribing information.
• Misrepresentation of safety information.
• Wrongful death.

Every case depends upon its unique facts, including medical history, prescribing decisions, timing of injuries, regulatory communications, and scientific evidence.

An experienced product liability investigation often involves reviewing FDA documents, adverse event reports, internal company records, medical records, pathology findings, prescribing information, and expert medical opinions.

Who May Be Eligible to File a Tavneos Lawsuit?

Individuals may wish to speak with an attorney if they or a loved one experienced serious complications after taking Tavneos.

Potential cases may involve:

• Drug-induced liver injury.
• Liver failure.
• Vanishing bile duct syndrome.
• Liver transplantation.
• Permanent liver damage.
• Hospitalization due to liver complications.
• Wrongful death following liver injury.

Every potential claim requires an individualized evaluation based upon medical records, diagnosis, medication history, and applicable state law.

Frequently Asked Questions About Tavneos Lawsuits

Can I file a lawsuit if I developed liver damage after taking Tavneos?

Possibly. Individuals who experienced drug-induced liver injury, liver failure, vanishing bile duct syndrome, or other serious complications after taking Tavneos may have legal claims. An attorney can review your medical records, treatment history, and the circumstances surrounding your injuries to determine whether you may qualify to pursue compensation.

What compensation may be available in a Tavneos lawsuit?

Depending on the facts of the case, compensation may include medical expenses, hospitalization costs, lost income, diminished earning capacity, future medical care, pain and suffering, emotional distress, permanent disability, and other damages recognized under applicable law. Families who lost a loved one may also have wrongful death claims under state law.

What is drug-induced liver injury?

Drug-induced liver injury, often called DILI, occurs when a medication damages the liver. Symptoms can include jaundice, nausea, vomiting, abdominal pain, fatigue, dark urine, itching, and abnormal liver function tests. Some cases improve after stopping the medication, while others progress to permanent liver damage or liver failure.

What is vanishing bile duct syndrome?

Vanishing bile duct syndrome is a rare condition in which the bile ducts inside the liver become damaged or disappear, interfering with normal bile flow. This condition can cause severe liver dysfunction and, in some patients, may require liver transplantation or result in death. The FDA identified several biopsy-confirmed cases associated with Tavneos in its recent safety communication.

Do I need proof that Tavneos caused my injuries?

Medical evidence is essential in any pharmaceutical product liability case. Your treating physicians, medical records, laboratory testing, pathology reports, medication history, and other documentation may help establish whether Tavneos contributed to your liver injury. Attorneys frequently work with medical professionals to evaluate causation and damages.

Contact Parker Waichman LLP For A Free Case Review

If you or someone you love developed serious liver damage, liver failure, vanishing bile duct syndrome, or another severe complication after taking Tavneos, you may have important legal rights. Prescription drug manufacturers have a responsibility to properly evaluate medication risks, monitor safety after approval, and provide timely warnings when serious adverse events emerge.

Parker Waichman LLP represents individuals and families nationwide in pharmaceutical product liability litigation involving dangerous medications and defective drugs. The firm offers free consultations to help injured patients understand their legal options and determine whether they may have a claim.

Call 1-800-YOUR-LAWYER (1-800-968-7529) today for a free consultation to discuss your potential Tavneos lawsuit. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.